Observational studyPacing and clinical electrophysiology : PACE2026
Long-Term Outcomes of Radiofrequency Atrioventricular Node Ablation in a Real-World Population.
Observational study in Pacing and clinical electrophysiology : PACE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile interventional strategies have expanded the options for long term rhythm restoration, rate control continues to play a pivotal role in the treatment of atrial arrhythmias; however, pharmacologic strategies alone often fail in achieving effective rate control.
aimsTo examine long-term outcomes in patients who have undergone atrioventricular node ablation (AVNA) for the management of symptomatic atrial arrhythmias.
methodsThis observational Study Assessed Patients Who Underwent AVNA For Rate Control of Atrial Fibrillation (AF) Or Atrial Tachycardia (AT) Between April 2014 and February 2022. Clinical data, along with follow-up information including cardiac device interrogation were analyzed. A composite safety endpoint, Encompassing Heart Failure (HF) Rehospitalization, lead revision, device infection, or upgrade for cardiac resynchronization therapy (CRT), was evaluated. Additionally, structured patient interviews were conducted to assess quality of life outcomes.
results192 patients (76 females (39.6%), mean age 73.7 ± 10 years) were included into the study. Patients suffered from paroxysmal AF in 10 cases (5.2%), persistent AF in 138 cases (71.9%) and AT in 44 cases (22.9%). Acute AVNA was successful in all patients. Two pseudoaneurysms at the femoral puncture site occurred as the only periprocedural complications. Mean follow-up duration was 907.0 ± 609.7 days. Persistent complete AV block was present in 191 patients (99.5%) during follow-up. The composite safety endpoint occurred in 58 (30.2%) patients. Quality of life significantly improved in most patients with a relevant regression in EHRA and NYHA scores.
conclusionAVNA is effective and safe in an all-comer patient population with high success rates in terms of rate control, QOL improvement and a favorable safety profile during long-term observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.